QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

21,782 signal articles · 481 in last 24h · 105,783 total before filter · latest 1h ago
481last 24h
2435last 7d
478● bullish (7d)
253● bearish (7d)
200publishers
AllMacro164Earnings1501M&A144Regulatory14Product8Analyst23
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Vertex (VRTX) Buys Crinetics To Push Beyond Cystic Fibrosis
Simply Wall St.2d agobullish
Vertex (VRTX) Buys Crinetics To Push Beyond Cystic Fibrosis

Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed to acquire Crinetics Pharmaceuticals in a deal expected to close in the third quarter of 2026. The transaction is designed to broaden Vertex's reach in biotech and add new disease areas beyond its core cystic fibrosis franchise. Investors are watching for the potential impact on Vertex's drug pipeline and competitive position as the companies work toward closing. Vertex Pharmaceuticals enters this deal with a sizeable track record in cystic...

Bloomberg2d agobullish
Eli Lilly Ripe for Stock Split After Obesity Drug-Fueled Rally

(Bloomberg) -- Wall Street’s appetite for weight-loss drug stocks over the past four years has powered Eli Lilly & Co. to consistently trade above $1,000 per share. Now, some see the pharma giant’s stock as primed for a split.Most Read from BloombergBeer Dynasty Families Sell €731 Million Stake in AB InBevApple’s New CEO Taps Retired Hardware Executive for Management TeamTaco Bell Met With Michigan on Parasite Weeks Before RecallMamdani Dismisses Business Leaders Advising NYC’s Mayor’s FundS&P 5

Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis
Reuters2d agobullish
Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis

Aug 4 () - Pfizer on Tuesday slightly raised the lower end of ‌its full-year revenue forecast after ‌beating Wall Street estimates for second-quarter profit, driven ​by strong demand for blood thinner Eliquis. Pfizer is banking on newer medicines to offset ‌fading COVID revenue ⁠and reduce reliance on aging blockbuster drugs, while investors look ⁠for signs that its $10 billion purchase of Metsera can help establish a meaningful ​presence in ​the fast-growing ​obesity market.

Bloomberg2d agobullish
Caterpillar Profit Tops Estimates as AI Boosts Power Sales

(Bloomberg) -- Caterpillar Inc. posted second-quarter earnings and revenue that beat Wall Street expectations as the company’s power-generation business continued to post strong growth off the back of data center spending.Most Read from BloombergBeer Dynasty Families Sell €731 Million Stake in AB InBevApple’s New CEO Taps Retired Hardware Executive for Management TeamTaco Bell Met With Michigan on Parasite Weeks Before RecallMamdani Dismisses Business Leaders Advising NYC’s Mayor’s FundS&P 500 C

Leidos (NYSE:LDOS) Exceeds Q2 CY2026 Expectations, Stock Soars
StockStory2d agobullish
Leidos (NYSE:LDOS) Exceeds Q2 CY2026 Expectations, Stock Soars

Defense contractor Leidos (NYSE:LDOS) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 7.2% year on year to $4.56 billion. The company expects the full year’s revenue to be around $18.3 billion, close to analysts’ estimates. Its non-GAAP profit of $3.26 per share was 12.1% above analysts’ consensus estimates.

How Investors May Respond To Freeport-McMoRan (FCX) Upgraded Copper-Gold Outlook And Ongoing Buybacks
Simply Wall St.2d agobullish
How Investors May Respond To Freeport-McMoRan (FCX) Upgraded Copper-Gold Outlook And Ongoing Buybacks

In July 2026, Freeport-McMoRan reported second-quarter 2026 results showing higher net income and earnings per share year over year, alongside broadly steady sales, and updated guidance forecasting significantly higher copper and gold sales in the second half of 2026 and into 2027. The company also continued its share repurchase program, having bought back 55,374,242 shares for US$2.20 billion since late 2021, which reduces the share count and may enhance per-share metrics over time. Next,...

Spotify Climbs to 300 Million Premium Subscribers
The Wall Street Journal2d agobullish
Spotify Climbs to 300 Million Premium Subscribers

Spotify Technology reached a milestone of 300 million premium subscribers in the second quarter while growing revenue by 14% in the period compared with a year earlier. Spotify added seven million premium subscribers in the second quarter, bringing its total to 300 million and beating the company’s prior guidance by one million. The Swedish audio streamer’s monthly active users grew by 12% year-over-year to 777 million, falling short of the company’s prior guidance by one million.